Darunavir Tablets and Orfadin (Nitisinone Capsules)
Determining the interaction of Darunavir Tablets and Orfadin (Nitisinone Capsules) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme. However, data evaluating the interaction are not available. MANAGEMENT: Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 Cerner Multum, Inc. "Australian Product Information." O 0 Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."
Professional:MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme. However, data evaluating the interaction are not available.
MANAGEMENT: Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."
Generic Name: darunavir
Brand name: Prezista
Synonyms: Darunavir
Generic Name: nitisinone
Brand name: Orfadin, Nityr
Synonyms: Orfadin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Darunavir Tablets-Orfadin (Nitisinone Oral Suspension)
- Darunavir Tablets-Orfadin Suspension
- Darunavir Tablets-Orfro
- Darunavir Tablets-Orgaran
- Darunavir Tablets-Orilissa
- Darunavir Tablets-Oritavancin
- Orfadin (Nitisinone Capsules)-Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide
- Orfadin (Nitisinone Capsules)-Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Fumarate
- Orfadin (Nitisinone Capsules)-Darvocet
- Orfadin (Nitisinone Capsules)-Darvocet A500
- Orfadin (Nitisinone Capsules)-Darvocet-N
- Orfadin (Nitisinone Capsules)-Darvon